Cullen and Dykman, 229 Nassau Street, Princeton 08542. 609-279-0900. Neil Yoskin, partner. www.sbflawfirm.com.
Cullen and Dykman’s Princeton office has expanded its environmental practice with the addition of lawyer Amie Kalac.
With more than 20 years of experience, Kalac represents corporate, municipal, and individual clients in an array of matters involving land use and the environment. She focuses her practice on counseling clients on identifying applicable federal and state environmental statutes, securing environmental and land use approvals, assuring regulatory compliance, and protecting their rights in enforcement matters or complex real estate transactions.
“Amie’s experience and reputation in the environmental field will be of enormous value to our clients. Her skills and ability to navigate the challenging environmental regulatory climate bolsters our already formidable environmental practice in New Jersey and New York,” said Cullen and Dykman’s managing partner Christopher H. Palmer.
Kalac earned her law degree from Western New England School of Law and her bachelor’s from Boston College.
Imbue Creative, 71 North Main Street, Ewing 08530. Michael Piperno, chief creative officer. www.imbuecreative.com.
Imbue Creative has hired Erin Klebaur as director of client success.
“We are extremely excited to have Erin join the team,” said Imbue President Michael Piperno. “As a brand ambassador with a successful track record of helping companies develop strategies to address their long-term goals, we’re looking forward to adding Erin’s solutions-centric mindset to our team’s approach to helping clients. While much of marketing today is driven by digital tools and data analytics, we know marketing is really about relationships — with real people. Erin shares this view with us, and she is a wonderful addition to the Imbue team.”
Prior to joining Imbue, Klebaur spent nearly 14 years at Creative Marketing Alliance, where she most recently served as director of client services.
“I am very excited and honored to be joining such a fantastic team of creative marketing professionals who collaborate to bring powerful solutions to prospective and existing clients,” Klebaur said. “By taking a consultative approach and having a passion for helping people succeed, we ensure our teams create solutions that inspire — and get results for our clients.”
Klebaur graduated from Rider University with a bachelor’s degree in communications, with a concentration in business and professional speech as well as a minor in marketing and advertising.
Integra LifeSciences Holdings Corporation (IART), 313 Enterprise Drive, Plainsboro 08536. 609-936-3600. Peter Arduini, CEO and president. www.integralife.com.
Integra LifeSciences Holdings Corporation, an Enterprise Drive-based medical technology company, has acquired Arkis Biosciences, a privately held Tennessee company. Akis offers a portfolio of neurosurgical devices, including the CerebroFlo external ventricular drainage catheter with Endexo technology, a permanent additive designed to reduce the potential for catheter obstruction due to blood clot formation.
“Neurocritical care is an important area of focus for Integra. We recently introduced our CereLink Intracranial Pressure Monitor and invested in clinical specialists to better support neurocritical care teams,” said Dan Reuvers, president of Codman Specialty Surgical, a division of Integra focused on neurosurgical products. “Today’s acquisition expands our leading portfolio to better treat patients and underscores our commitment to addressing unmet needs in patient care.”
Catheter obstruction and bacterial colonization are two key challenges healthcare teams face in managing the external drainage of cerebrospinal fluid in neurocritical care patients. This acquisition adds to Integra’s current portfolio of devices that address bacterial colonization, catheter obstruction, and other issues.
“The introduction of the CerebroFlo EVD Catheter first established the benefits of Endexo in neurocritical care,” said Chad Seaver, CEO of Arkis Biosciences. “As a world leader in neurosurgery, Integra is the right choice to extend the reach of this important technology to patients and clinicians worldwide.”
EVD catheters are used in combination with a variety of EVD systems for external drainage of CSF to manage elevated intracranial pressure in patients with acute brain injury and hydrocephalus. Reducing complications associated with EVD management, such as bacterial colonization on the EVD catheter surface or catheter obstruction, is fundamental to the practice of neurocritical care.
WIRB Copernicus Group, 212 Carnegie Center, Suite 301, Princeton 08540. 609-945-0101. Donald A. Deieso, chairman and CEO. www.wcgclinical.com.
The WIRB-Copernicus Group’s Clinical Services Division, based in Carnegie Center, announced the acquisition of PharmaSeek, LLC, including its wholly owned subsidiaries PFS Clinical and PatientWise. The companies are providers of administrative, consulting, patient recruitment, and training for clinical research sites. PharmaSeek, which has been in business for 25 years, does administrative work for scientists and independent sites, including study identification, contract and budget negotiation, coverage analysis, financial management, and patient recruitment.
“At WCG we are proud to support the members of the research ecosystem with best-of-breed solutions to optimize their participation in clinical trials,” said Donald A. Deieso, executive chairman and CEO of WCG.
“Sites are the connective tissue that unites all of the elements of clinical research; sites are where sponsors and patients come together, and where science and execution intersect. It is in the best interest of the entire research ecosystem that we help our existing sites to remain healthy and vital, and that we make research more accessible and manageable for new investigators.
“We are delighted to welcome PharmaSeek — an organization dedicated to increasing the efficiency, profitability and vitality of clinical research sites — to our family of companies. We look forward to expanding PharmaSeek’s presence in the market and to providing investigators, institutions and independent sites with more robust support in the management of their research.”
“We are thrilled to join WCG, and to be part of an organization so keenly focused on driving down the cost of drug development,” said Nicolas Cindric, PharmaSeek’s CEO. “It doesn’t feel like an acquisition in the traditional sense; it feels more like we’ve received an exclusive invitation to join a community of like-minded professionals who share vision for a better tomorrow. I am delighted that, through this transaction, we will be able to offer even greater value to the ecosystem we serve.”
Like WCG’s previous acquisitions, PharmaSeek will continue to operate independently and retain its headquarters in Madison, Wisconsin. WCG will provide PharmaSeek with access to capital, expertise and corporate operational support.